NCT04912687

Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients

Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced Non-small Cell Lung Cancer Patients (NSCLC)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 581 (actual)
• Sponsor: Institut Bergonié · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Multicenter prospective cohort study aiming to evaluate the detection rate of EGFR gene mutation in patients with advanced NSCLC in a real-word clinical setting, based on liquid biopsy and tissue analyses.

Detailed description

This a multicenter prospective cohort study. This study will be proposed to newly diagnosed advanced NSCLC patients. For included patients, archived paraffin embedded tumor tissue will be used for sequencing ; and blood sample will be collected for research purpose (plasma DNA collection and sequencing). Both tissue and liquid biopsy samples will follow usual processes and will be sent to the Molecular Pathology laboratory of the Investigation center.

Conditions

• Non Small Cell Lung Cancer
• Advanced Solid Tumor

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	EGFR gene mutation analysis on liquid biopsy	Blood samples will be collected at inclusion for plasma DNA collection and analysis.

Timeline

• Start date: 2022-01-01
• Primary completion: 2026-01-17
• Completion: 2026-01-17
• First posted: 2021-06-03
• Last updated: 2026-03-06

Locations

9 sites across 1 country: France